NPPB and hydrops fetalis: No significant effect in cardiovascular death was observed.Compared to DAPA-HF trial, it enrolled patients with a lower left ventricularejection fraction (LVEF), higher N-terminal prohormone B-type natriuretic peptide(NT-proBNP) levels and higher use of device and angiotensin receptor-neprilysininhibitor (ARNI) therapy.